Results 81 to 90 of about 69,629 (300)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease

Therapeutic Advances in Neurological Disorders, 2018
Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa–levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration.
Jason Margolesky, Carlos Singer
doaj   +1 more source

Fiber‐type soft bioelectronics for wearable and implantable sensing and therapy

BMEMat, EarlyView.
Fiber‐type soft bioelectronics are emerging as versatile platforms for wearable and implantable health monitoring and therapeutic applications. These bioelectronics use organic and inorganic matrices combined with advanced fillers, which feature high conductivity, electrochemical sensitivity, softness, and biocompatibility.
Haneul Kim, Hak Yong Kim, Ja Hoon Koo, Gi Doo Cha, Dae‐Hyeong Kim, Hye Jin Kim   +5 more
wiley   +1 more source

Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism

Frontiers in Neurology, 2019
Although the administration of dopamine precursor levodopa remains as the mainstay for the treatment of Parkinson's disease, long-term exposure to levodopa often causes a disabling complication, referred to as levodopa-induced dyskinesias. Therefore, the
Masatoshi Ogawa, Masatoshi Ogawa, Yu Zhou, Yu Zhou, Ryosuke Tsuji, Ryosuke Tsuji, Jiro Kasahara, Jiro Kasahara, Satoshi Goto, Satoshi Goto   +9 more
doaj   +1 more source

Characterization of Vitamin B12 Supplementation and Correlation with Clinical Outcomes in a Large Longitudinal Study of Early Parkinson's Disease. [PDF]

, 2019
ObjectiveIn Parkinson's disease (PD), vitamin B12 levels are lower, and comorbid B12 deficiency has been associated with the development of neuropathy and early gait instability.
Christine, Chadwick W, Dietiker, Cameron, Kim, Soeun, Zhang, Yunxi   +3 more
core  

Toward personalized healthcare: Advances in two‐dimensional nanomaterial‐based flexible electrochemical sensors for physiological monitoring

BMEMat, EarlyView.
This review provides an overview of the properties, composites and application of two‐dimensional (2D) nanomaterials for wearable electrochemical biosensors. Also, the challenges and future prospects of utilizing 2D nanomaterials in wearable electrochemical biosensor applications are discussed.
Kou Zhang, Lu Han, He‐Qing Cai, Xin‐Yu Xue, Yi‐Fei Song, Wu‐Lin Xin, Ying‐Ze Wang, Peng Liu, Juan Liu   +8 more
wiley   +1 more source

Effect of Rectal Levodopa Administration: A Case Report

Case Reports in Neurology, 2015
Objective: The aim of this report is to discuss whether or not rectal levodopa administration is useful in some situations. Background: In situations where oral intake of levodopa formulations is not possible, the treatment options of Parkinson's disease
Jolanda M.J. Vogelzang, Marianne Luinstra, A. Wijnand F. Rutgers   +2 more
doaj   +1 more source

Altered intrinsic functional coupling between core neurocognitive networks in Parkinson\u27s disease [PDF]

, 2015
Parkinson3s disease (PD) is largely attributed to disruptions in the nigrostriatal dopamine system. These neurodegenerative changes may also have a more global effect on intrinsic brain organization at the cortical level.
Cronin-Golomb, Alice, James, Amy C., Putcha, Deepti, Ross, Robert S., Stern, Chantal E.   +4 more
core   +1 more source

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Contribution of dopaminergic polymorphisms to levodopa treatment response and drug concentration in Chinese patients with Parkinson’s disease

Clinical Parkinsonism & Related Disorders
Background: Levodopa is the mainstay of treatments for Parkinson’s disease (PD), but large heterogeneity exists in patient response. Pharmacogenetic studies highlighted that genetic factors may play a relevant influence in this drug response variability.
Xiaoqin He, Kai Shi, Chengjun Mo, Yi Zhang, Qin Xiao, Xiaodong Yang   +5 more
doaj   +1 more source

Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. [PDF]

, 2018
In November 2012, a 72-year old patient was diagnosed with left eye wet age-related macular degeneration. The patient received three monthly intravitreal injections of ranibizumab, with complete resolution of retinal hemorrhage and edema and ...
Antonini, Bodis-Wollner, Brilliant, Brown, Chung, Cutroneo, de Jong, Ding, Drake, Enders, Falk, Gibson, Kemp, Krum, Miners, Naranjo, Nowacka, Nowacka, Piltonen, Pitzer, Poewe, Postuma, Pratt, Quittet, Rosenfeld, Shamloo, Sheikh, Silverman, Slotnick, Stewart, Storkebaum, Tian, Trost, Ueta, Whitton, Wu, Yasuda, Yasuhara, Yasuhara, Yasuhara, Yla-Herttuala, Yue, Zachary, Zehetner   +43 more
core   +2 more sources